|
|
|
Click Here to return To Results
|
|
The nature of antibody, and to a lesser extent the clinical syndrome, determines the risk and type of an underlying malignancy. For screening of the thoracic region, a CT-thorax is recommended, which if negative is followed by fluorodeoxyglucose-positron emission tomography (FDG-PET). Breast cancer is screened for by mammography, followed by MRI. For the pelvic region, ultrasound (US) is the investigation of first choice followed by CT. Dermatomyositis patients should have CT-thorax/abdomen, US of the pelvic region and mammography in women, US of testes in men under 50 years and colonoscopy in men and women over 50. If primary, screening is negative, repeat screening after 3-6 months and screen every 6 months up till 4 years. In LEMS, screening for 2 years is sufficient. In syndromes where only subgroup of patients have a malignancy, tumour markers have additional value to predict a probable malignancy. |
|
(click to filter results - removes previous filter)
carcinoma CAT scan,abdomen CAT scan,chest CAT scan,emission CAT scan,pelvis encephalitis,paraneoplastic limbic encephalitis lymphoma malignancy screen mammogram MRI MRI,abnormal MRI,whole body neurologic complications of,systemic cancer prognosis remote effect of cancer on the nervous system screening ultrasonography ultrasonography,pelvis ultrasonography,testes whole body imaging
|
Click Here to return To Results
|
|